Shaolin Capital Management’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

Shaolin Capital Management’s Portfolio PBAXU Stock Details PBAXU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-750,000	Closed	-$7.57M	–	829
2022 Q3	$7.57M	Hold	750,000	–	–	0.21%	140
2022 Q2	$7.55M	Hold	750,000	–	–	0.18%	144
2022 Q1	$7.54M	Hold	750,000	–	–	0.19%	131
2021 Q4	$7.57M	Buy	+750,000	New	+$7.59M	0.19%	123

Other funds holding PBAXU

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Shaolin Capital Management's PBAXU Position: Q4 2022 in Review

Shaolin Capital Management sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q4 2022, closing a stake of 750,000 shares — an estimated $7.57M sold.

Shaolin Capital Management first reported a position in PBAXU in Q4 2021 and held it in 4 quarters. The position peaked at $7.57M in Q3 2022. 3 funds tracked by Wall St. Rank hold PBAXU as of Q4 2022.

Shaolin Capital Management reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
Shaolin Capital Management sold 750,000 Phoenix Biotech Acquisition Corp. Unit shares in Q4 2022, an estimated $7.57M.
Shaolin Capital Management first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q4 2021 and held it in 4 quarters.
Shaolin Capital Management's Phoenix Biotech Acquisition Corp. Unit position peaked at $7.57M in Q3 2022.
3 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q4 2022.

Based on Shaolin Capital Management's 13F filing for Q4 2022, filed 15 Feb 2023.